Screener
Amneal Pharmaceuticals, Inc. AMRX Oral liquid — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Auto-Injector | 62,214 | 66,594 | 104,126 | 114,754 |
| Injectable | 56,783 | 34,646 | 106,721 | 69,434 |
| Biosimilar | 29,128 | 25,248 | 51,429 | 53,788 |
| Oral liquid | 10,371 | 17,879 | 22,463 | 41,427 |
| Other dosage forms (1) | 81,594 | 68,185 | 128,206 | 124,607 |
| Subtotal dosage forms | 482,300 | 431,524 | 900,218 | 844,998 |
| International | 7,613 | 1,901 | 12,932 | 3,135 |
| Total Affordable Medicines net revenue | 489,913 | 433,425 | 913,150 | 848,133 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s oral liquid — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported oral liquid — net revenue of $10.37M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s oral liquid — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s oral liquid — net revenue decreased by 42.0% year-over-year, from $17.88M to $10.37M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s oral liquid — net revenue?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s oral liquid — net revenue has grown at a -12.4% compound annual growth rate (CAGR), from $108.41M to $72.82M.
- What does oral liquid — net revenue mean?
- This metric represents the total gross sales generated from the oral liquid pharmaceutical product line, adjusted for returns, allowances, and rebates. It serves as a key indicator of market demand and commercial performance for this specific dosage form within the company's broader generics portfolio. Tracking this revenue stream helps investors assess the stability and growth trajectory of liquid-based medication offerings relative to other delivery systems.
Ask your AI about Amneal Pharmaceuticals, Inc.'s oral liquid — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude